Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Treatment of the Elastic Phase of Chronic Myelogenous Leukemia with High-Dose Cytosine Arabinoside

Ernst, Timothy J., M.D.; Rosenthal, David S., M.D.; Griffin, James D., M.D.; Canellos, George P., M.D.

American Journal of Clinical Oncology: December 1988 - Volume 11 - Issue 6 - p 623–626
Original Article: PDF Only

Sixteen patients with accelerated or blastic phase chronic myelogenous leukemia were treated with high-dose cytosine arabinoside given at 3 g/m2 every 12 h for two to eight doses per course. All patients had an immediate clearing of peripheral blood blast cells. Five patients achieved a complete response for 1–14 months, median 4.5 months. Toxicity was significant and predictable on the basis of dose given. We have identified both an effective and a toxic dosing schedule. The rapid response is dramatic but relatively short-lived, and suggests that additional agents in conjunction with reinfusion of autologous stem cells may offer these patients a greater chance of significant response.

From the Divisions of Tumor Immunology (T.J.E., J.D.G.) and Medical Oncology (G.P.C.), Dana-Farber Cancer Institute; the Division of Hematology (D.S.R.), Brigham and Women's Hospital; and the Department of Medicine, Harvard Medical School, Boston, Massachusetts.

© Lippincott-Raven Publishers.